Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Neoplasm malignant+4

Recruiting

InvestigationalNo placebo

Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Imsidolimab

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Neoplasm malignant+7

Recruiting

Registered drugNo placebo

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Ipilimumab

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of [90Y]Y-PentixaTher in Patients with Recurrent or Resistant CNS Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Gallium (68Ga)

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

Study on BI-1808 and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Bi-1808

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

Study of drug combination in patients with advanced cancer based on genomic profiling - ProTarget Danish nationwide trial

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Cobimetinib

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

Study on the Safety and Effects of OBT076 and Balstilimab in Patients with Recurrent or Metastatic CD205-Positive Solid Tumors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Balstilimab

Contact Research Centre

Neoplasm malignant

Recruiting

Registered drugNo placebo

Study of Durvalumab alone and in combination with Tremelimumab in children with advanced solid tumors and blood cancer

Registered drugNo placebo

Spain

Participants:0–17 years
Substances:Durvalumab

Contact Research Centre

Neoplasm malignant

Recruiting

InvestigationalNo placebo

Study on 68Ga-FAPI-46 for Imaging Pancreatic, Stomach, Bile Duct, and Ovarian Cancers in Patients with Solid Tumors

InvestigationalNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate